We rank companies based on fund manager, research analyst and news sentiment
ABT stock icon

Abbott
ABT

$105.9
2.98%
 

About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Employees: 114,000

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 13 analysts
0
News positive %
of 48 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

62% more first-time investments, than exits

New positions opened: 284 | Existing positions closed: 175

23% more funds holding in top 10

Funds holding in top 10: 84 [Q3] → 103 (+19) [Q4]

21% more call options, than puts

Call options by funds: $1.22B | Put options by funds: $1.01B

16% more capital invested

Capital invested by funds: $124B [Q3] → $143B (+$19.7B) [Q4]

4% more funds holding

Funds holding: 2,612 [Q3] → 2,721 (+109) [Q4]

1.6% more ownership

Funds ownership: 73.43% [Q3] → 75.02% (+1.6%) [Q4]

20% less repeat investments, than reductions

Existing positions increased: 926 | Existing positions reduced: 1,164

Research analyst outlook

13 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$107
1%
upside
Avg. target
$124
17%
upside
High target
$141
33%
upside

13 analyst ratings

12 positive
92%
neutral
8%
negative
0%
Evercore ISI Group
Vijay Kumar
18%upside
$125
Outperform
Maintained
4 Apr 2024
Citigroup
Joanne Wuensch
21%upside
$128
Buy
Maintained
3 Apr 2024
RBC Capital
Shagun Singh
21%upside
$128
Outperform
Reiterated
14 Feb 2024
Barclays
Matt Miksic
33%upside
$141
Overweight
Maintained
26 Jan 2024
Citigroup
Joanne Wuensch
19%upside
$126
Buy
Maintained
25 Jan 2024

Financial journalist opinion

Based on 48 articles about ABT published over the past 30 days